Anticoagulant

6 Drugs classified under this drug class

Anticoagulant. Fondaparinux (sodium) 2.5 mg/0.5 ml, 0.75 mg/ 0.6 ml.
PRE-FILLED SYR. (sol., for inject.): 10 x
0.5 ml x 2.5 mg, 10 x
0.6 ml x 0.75 mg. See lit.
Prevent. VTE in pts. undergoing major
orthoped. surg. lower limbs. Prevent. VTE in
pts. undergoing abdom. surg. who are at high risk thromboembol. complicats.
Prevent. VTE in medical pts. at high risk for
VTE and immobilised due to acute illness
such as card. insuffic. and/or acute respirat.
disords, and/or acute infects. or inflamm.
dis. Tmt. unstable angina or non-ST segm.
elevat. myocard. infarct. (UA/NSTEMI) in
pts. where urgent invas. manage. (PCI) not
indicat. Tmt. ST segm. elevat. myocard.
infarct. (STEMI) in pts managed with
thrombolytics or who are not to receive
other form reperfus. ther.
C/I: Hypersens., active clin. bleed., acute
bact. cardit., severe ren. fail. (creatinine
clear. <20 ml/min).

Anticoagulant. Warfarin (sodium) 1, 2, 2.5, 5 mg.
TABS: 30 x 1 mg, 2 mg,
2.5 mg, 5 mg. See lit.
Proph.and/or tmt. ven. thromb. (and its
extension), pulm. embolism, proph. and/
or
tmt. thromb. embol. complicats. assoc.
with atrial fibrill. and/or card. valve
replace., reduce risk death, recur. M.I.,
stroke, system. embol. aft. M.I.
C/I: Hypersens., pregn., hemorrh., bleed.
tendencies, blood dyscras., recent/
complic. surg., threat. abort., eclamps.,
pre-eclamps.

Anticoagulant, Direct Factor Xa Inhibitor. Apixaban 2.5 mg, 5 mg.
F.C. TAB: 60 x 2.5mg, 60 x 5mg
Preven. of VTE (VTEp): elective hip or
knee replac. surg.- 2.5 mg ×2/d.
Init. dose should be taken 12 - 24 hrs.
after surg.
In pts. underg. hip replac. surg.- The
recom. duration of tmt. is 32- 38 d.
In pts. underg. knee replac. surg.: The
recom. duration of tmt. is 10- 14 d.
Preven. of stroke & syst. embol. in pts.
with non-valvul. atrial fibril. (NVAF):
5 mg ×2/d.
Dose reduction: 2.5mg×2/d in pts. with
NVAF and at least two of the follow.
characteristics: age ≥ 80 yrs., bdy. wt. ≤
60 kg, or ser. Cr ≥ 1.5 mg/dL (133
micromole/L).
Ther. should be cont. long term.
Tmt. of DVT, tmt. of PE and preven. of
recur. DVT &PE (VTEt)
Tmt. of acute DVT and tmt. of PE is 10
mg×2/d for the first 7 d. follow. by 5
mg ×2/d.
As per avail. med. guidelines, short
durat. of tmt. (at least 3 mnths.) should
be based on transient risk factor. (e.g.
recent surg., trauma, immobilis.).
Preven. of recur. DVT & PE is 2.5
mg×2/d. When preven. of recur. DVT &
PE is indic., the 2.5 mg×2/d should be
init. follow. complet. of 6 mnths. of tmt.
5 mg×2/d or with another anticoag.
See Lit.
2.5 mg tabs. - Preven. of VTE in adult pts.
who have undergone elect. hip or knee
replac. surg.
Preven. of stroke and syst. embol. in adult
pts. NVAF, with one/ more risk fact., e.g as
prior stroke, TIA; age ≥ 75 yrs.; hypertens.;
diabetes. mell.; symptom. HF (NYHA Class
≥ II).
Tmt. of DVT, PE , and preven. of recur.
DVT & PE in adult.
5 mg tabs. - Preven. of stroke, syst. embol.
in adult pts. NVAF, with one/ more risk
fact., e.g. prior stroke or TIA; age ≥ 75 yrs.;
hypertens.; diabetes mell.; symptom. HF
(NYHA Class ≥ II).
Tmt. of DVT, PE in adult. 
C/I: Hypersens.
Active clinic. signific. bleed.
Hep. dis. assoc. with coagulopathy
&clinic. relevant bleed. risk.
Lesion/ condit. if consid. a signific. risk
factor for major bleed. This may include
current or recent GI ulcer., presence of
malig. neoplasm. at high risk of bleed.,
recent brain, spinal inj., recent brain,
spinal or ophthalmic surg., recent
intracran. haemorrhage, known/
suspect. esophagi. varices, arterioven.
malform., vasc. aneurysms or major
intraspinal or intracerebr. vascular
abnorm.
Concom. tmt. with any other anticoag.
agent e.g. unfraction. heparin (UHF), low
molec. wt. heparins (enoxaparin,
dalteparin, etc.), heparin derivat.
(fondaparinux, etc.), oral anticoag.
(warfarin, rivaroxaban, dabigatran, etc.)
except under specific circumstances of
switching anticoag. ther.or when UHF is
given at doses necessary to maintain an
open centr. ven. or arterial catheter.

Anticoagulant. Heparin Sodium 10 IU/ml, 100 IU/ml.
SINGLE DOSE VIAL: 10 IU/ml; 100 IU/ml x
20 x 10 ml. See lit.
Maint. potency I.V. device. May be used
foll. initial placement of device in vein or
aft. withdrawal of blood lab. analysis.
C/I: Hypersens., severe
thrombocytopen., uncontrolled active
bleed. See lit.

Anticoagulant. Heparin 25,000 IU / 5 ml.
VIALS: 25 x 5 ml. I.V./S.C.
See lit.
Thrombo-embol. disords., proph. deep
vein thromb., thrombo-embol. events.

Anticoagulant. Heparin Sodium 25000 IU / 5 ml.
VIAL (Sol. for inj./infus.): 1×25000IU/5ml.
Dosage must be individ.  adjust.
Prevent. of thromboembol. disord. As part of the tmt. of ven. and arter. thromboembol. disord. (includ.  early tmt. of heart attacks as well as unst. angina. pect.). For the anticoagulant. in case of tmt. or operation with extracorporeal circul. (e.g.heart-lung machine, hemodialysis).
C/I: Hypersens. Current/ prev. hist. of heparin-induced allergic thrombocytop. (type 2). Disorders assoc.  with a bleed. diathesis, e.g. thrombocytop., coagulopathies, sev. hep./renal/pancreat. disord. Disord. in which there is a suspect. lesion of the vascul. syst., e.g. GI ulc., hypertens. (>105 mm Hg diastolic), cereb. haemorrhage, traum. or surg. operat. involve. the  CNS, eye operat., retinopathies, vitreous  haemorrhage, aneurysm of the cereb. arteries, infect. endocarditis. Threatened miscarriage - Spinal anaesthesia, epid. anaesthesia, lumb. punct. - Organ lesions assoc. with a bleed. tendency. Use in preterm/newborns dueto benzyl alcohol content.